Trial | NCT01819649  Report issue

Title

Selenium in the Prevention of Cancer
Prevention of Cancer by Intervention With Selenium - A Pilot Study in a Danish Population

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    high-selenium yeast ...

  • Study Participants

    491
This is a pilot study proceeding an intended international trial.

Hypothesis: Daily intake of selenium supplementation in the form of selenium-enriched yeast tablets will reduce the risk of cancer in healthy individuals.

Objective: The objective of this pilot study was to assess the viability of a full scale randomised trial.

AMENDMENT TO STUDY OBJECTIVE: Mortality analysis during intervention and follow-up as specified in the sections concerning study design and outcome measures.
Study Started
Nov 30
1998
Primary Completion
Jun 30
2004
Study Completion
Jun 30
2004
Last Update
Sep 14
2017

Dietary Supplement SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S

Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d Experimental

Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d Experimental

Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d Experimental

Yeast tablet Placebo Comparator

Criteria 

Inclusion Criteria:

WHO performance status 0 or 1
No active liver- or kidney disease (Serum ALAT (alanine aminotransferase), alkalic phosphatase, bilirubin, creatinin or urea within 2 S.D of laboratory reference range)
No previous cancer diagnosis
No known HIV-infection
Participant must understand oral and written information
Participant must not use selenium supplementation of above 50 mcg/d
Participant must give written consent prior to inclusion
No Results Posted